Continuing Education CE I n the United States, the epidemiology of viral hepatitis, most commonly caused by hepatitis A, B, or C viruses, has changed dramatically over the past three decades. With the development of vac cines for hepatitis A and B viruses and the introduc tion of universal precautions and blood supply safety measures, hepatitis A virus (HAV) and hepatitis B virus (HBV) infection rates have declined by 88% and 64%, respectively, since 2000.
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n the United States, the epidemiology of viral hepatitis, most commonly caused by hepatitis A, B, or C viruses, has changed dramatically over the past three decades. With the development of vac cines for hepatitis A and B viruses and the introduc tion of universal precautions and blood supply safety measures, hepatitis A virus (HAV) and hepatitis B virus (HBV) infection rates have declined by 88% and 64%, respectively, since 2000. 1 By contrast, after years of stable or declining rates, the incidence of hepatitis C virus (HCV) infection has increased by 75% since 2010. 1 In 2011, the U.S. Department of Health and Human Services (HHS) released the first national, comprehensive, multiagency action plan for preventing and treating viral hepatitis. 2 The HHS action plan, which was updated in 2014, out lines measures that can be taken to improve health outcomes for people infected with HBV and HCV, both of which can progress to chronic disease that often produces minimal symptoms before resulting in cirrhosis or hepatocellular carcinoma. 3 With new recommendations calling for wider screening, the for at least 10 years and 99% of children for five to six years. 10 Children, who are generally asymptomatic, have played an important role in transmitting HAV. Al though initial recommendations for HAV vaccination among children focused on states with high incidence rates, the recommendation has since been expanded to include all infants, starting at one year of age, as part of the primary childhood immunization series. 10 Unvaccinated adults should be considered for HAV vaccination if they are at risk for exposure or severe adverse consequences of infection (see HAV Vaccination Recommendations 10 ). HBV is transmitted by percutaneous or mucosal exposure to the body fluids of an infected person. 11 In
By Corinna Dan, MPH, RN, Michelle Moses-Eisenstein, MPH, and Ronald O. Valdiserri, MD, MPH approval of new therapies that can cure more than 90% of those with chronic HCV, and the introduc tion of noninvasive technology for evaluating liver fibrosis, nurses are positioned to play a critical role in this plan-providing the clinical leadership and patient counseling that can • reduce the number of new viral hepatitis infec tions.
• ensure that existing infections are diagnosed.
• minimize the impact of chronic infection on the patients they care for and the communities they serve. This article reviews the epidemiology and diagnosis of HAV, HBV, and HCV; discusses the natural history of chronic HBV and HCV; and outlines the HHS ac tion plan, focusing on the role of nurses in prevention, treatment, and-in the case of HCV-cure.
SYMPTOMS, EPIDEMIOLOGY, AND PREVENTION

In the acute phase of infection, HAV, HBV, and HCV may produce similar symptoms (see Common Signs and Symptoms of Acute Viral Hepatitis A, B, and C).
The viruses, however, differ from each other in terms of mode of transmission, natural history, and vaccine availability (see Table 1 1, 4, 5 ). HAV is spread primarily through the fecal-oral route, either from person to person, or through ex posure to contaminated food or water. 4 Typically, the virus causes a selflimited infection of less than two months' duration, which confers immunity when re solved. 4 Most acute infections (85%) are symptom atic. 6 In rare cases, acute HAV infection can result in death. In 2012, the Centers for Disease Control and Prevention (CDC) received 1,562 case reports of HAV-a number estimated to represent as many as 3,050 actual cases, since, as with HBV and HCV, some infected patients are asymptomatic and some fail to seek care and testing. 1, 6 For HAV, each reported case is believed to represent nearly two actual infec tions. 6 In primate studies, HAV has remained infec tious on environmental surfaces for more than a month. 7 Preventive measures include vaccination, proper hand hygiene, and proper food handling, as well as disinfection of contaminated surfaces.
A safe and effective vaccine for HAV has been available in the United States since 1995. In 1999, the Advisory Committee on Immunization Practices called for the routine vaccination of children living in 17 states with consistently high HAV incidence rates. 8, 9 By 2003, those states saw an 88% drop in HAV incidence-to 2.5 cases per 100,000 popula tion from the average rate of 21.1 cases per 100,000 population recorded in the prevaccination period. 10 The series of two HAV vaccinations administered over a sixmonth period was shown to protect adults the United States, the most common modes of HBV transmission are sexual contact and injection drug use. 1, 4 Perinatal transmission is estimated to have oc curred in 1,058 of all U.S. births in 2009. 12 In 2012, the CDC received reports of 2,895 cases of acute HBV infection, suggesting that the actual number of new cases in the United States (including asymptomatic patients and those who seek no care) was actually closer to 19,000, 1 as each reported case of HBV is estimated to represent roughly 6.5 actual infections. 6 Acute infection is symptomatic in up to 50% of adult cases; infants and children are usually asymptomatic. 4 Acute HBV infection most often re solves completely and confers lifelong immunity, but in up to 2% of cases, infection results in fulminant hep atitis, which has a case fatality rate of 63% to 93%. 4 Acute HBV progresses to chronic infection in about 90% of infants infected at birth, 30% to 50% of children ages one to five, and 5% of adults.
1 Peo ple with a compromised immune system are at ele vated risk of developing chronic infection. Those with chronic infection tend to be asymptomatic car riers, though roughly 25% eventually develop cir rhosis or hepatocellular carcinoma. An estimated 240 million people worldwide and 700,000 to 1.4 million people in the United States are chronically infected with HBV. 1, 13 HBV is considered hardy and remains infectious outside the body for about seven days. 4 To prevent HBV infection, people are advised to get vaccinated, avoid unprotected sexual contact, and avoid percuta neous or mucosal contact with infected blood, body fluids, and items that have been in contact with po tentially infected blood or body fluids, such as nee dles and other equipment used to inject drugs.
A safe and effective vaccine for HBV has been available since 1986. 4 It was first used to protect adults at risk, but a comprehensive infant and child hood vaccination strategy was introduced in 1991 (see HBV Vaccination Recommendations 1417 ).
14 Be tween 2000 and 2012, the rate of new HBV infections in the United States declined by 64%, primarily be cause of this effective immunization strategy. 1 In adults, the series of three HBV vaccinations should be admin istered within a sixmonth period regardless of age, with no need to restart the series if the intervals be tween injections exceed recommendations. 4 (CDC vaccine recommendations for infants, children, and adolescents can be found at www.cdc.gov/vaccines/ hcp/aciprecs/vaccspecific/hepb.html.) Three doses of the vaccine provide protection for 98% to 100% of vaccinated infants and 90% to 95% of vaccinated adolescents and adults. 4 HCV is transmitted parenterally, usually through injection drug use and less frequently through poor infection control practices during health care proce dures. 18 Sexual transmission occurs rarely, though among both men who have sex with men and hetero sexuals, the likelihood of sexual transmission rises with the number of sex partners and when sex part ners are coinfected with HIV. 1820 In addition, there is evidence that men who have sex with men and take HIV preexposure prophylaxis may be at risk for sexual transmission of HCV if they have unprotected sex with HCVinfected partners. 21 In 2012, the CDC received reports of 1,778 cases of acute HCV infection, 1 which suggests that the actual number of acute cases was 21,869, since each reported case is estimated to represent 12.3 actual cases. 6 The CDC also documented a 75% increase in new HCV infections between 2010 and 2012 and linked the in crease to rising injection drug use, primarily among
Common Signs and Symptoms of Acute Viral Hepatitis A, B, and C
• fever
Chronic HCV infection is the leading cause of liver-related death and hepatocellular carcinoma in the Western world.
white adolescents and young adults who reside in non urban settings. 1 Acute infection progresses to chronic disease in 75% to 85% of cases. 1 Infection is usually asymp tomatic, even in the presence of mild to severe liver disease. 1 Chronic HCV infection is the leading cause of liverrelated death and hepatocellular carcinoma in the Western world, with persistent inflammation causing cirrhosis within 30 years in 10% to 20% of those infected and putting 1% to 5% of these pa tients at annual risk for hepatocellular carcinoma. 5 As many as 150 million people worldwide and up to 3.9 million people in the United States are chroni cally infected with HCV. 1, 13 Little is known about the 
HAV
HAV is transmitted through ingestion of fecal matter, even in microscopic amounts, from • close contact with an infected person.
• sexual contact with an infected person.
• ingestion of contaminated food or drinks.
No Yes Yes
HBV HBV is transmitted through contact with infectious blood, semen, and other body fluids, primarily through • sexual contact with an infected person (most common HBV transmission route among U.S. adults).
• birth to an infected mother.
• sharing of contaminated needles, syringes, or other injection drug equipment.
• sharing of items such as razors or toothbrushes with an infected person.
• needlestick or other sharp-instrument injuries.
• direct contact with the blood or open sores of an infected person.
• transfusions of blood or blood products prior to universal blood donor screening.
Yes Yes Yes
HCV HCV is transmitted through contact with infectious blood, primarily through • sharing of contaminated needles, syringes, or other injection drug equipment (most common risk factor for new HCV cases).
• transfusions of blood or blood products prior to 1992.
HCV is less commonly transmitted through • sexual contact with an infected person.
• sharing of items such as razors or toothbrushes with an infected person. HCV is considered very hardy; a recent study found that cell culture-derived HCV can remain in fectious on surfaces up to six weeks, suggesting that accidental contact with contaminated surfaces may be a source of health care-associated transmission. 22 In light of these findings, health care providers would be well advised to avoid percutaneous exposure to in fected blood. Currently there is no vaccine for HCV.
Yes No No
SEROLOGIC TESTING FOR VIRAL HEPATITIS
To confirm a specific diagnosis of HAV, HBV, or HCV, serologic testing is required (see Table 2 1, 16, 18, 36 ). Screening tests are generally conducted on asymp tomatic people with an increased probability of hav ing or developing a disease, whereas diagnostic testing is conducted to establish the presence of a disease, typically in patients who are symptomatic. Previous screening strategies for HBV and HCV were based on the identification of such potentially stigmatizing risk factors as a history of injection drug use or unpro tected sex with multiple partners, which were seldom assessed by providers or disclosed by patients. Be cause this strategy failed to identify many patients who were chronically infected with HBV or HCV, the CDC and the U.S. Preventive Services Task Force (USPSTF) now recommend expanded HBV and HCV serologic screening for all people considered to be at high risk as well as for members of groups known to have high prevalence rates, such as people born be tween 1945 and 1965 and those born in certain coun tries or regions. 11, 2325 Both HBV and HCV serologic screening of patients at high risk for infection are Grade B USPSTF recommendations, meaning that they qualify as preventive services covered without copay under the Affordable Care Act (ACA).
HBV serologic screening is recommended for the following groups 11 24, 26 :
• people with HIV infection • anyone who has ever used injection drugs (even once) • health care, emergency medical, and public safety workers after needlestick injury or mucosal expo sure to HCVcontaminated blood • children born to mothers who test positive for HCV HCV screening is a two-step process. People rec ommended for screening should first be tested using an HCV antibody test. A positive antibody test indi cates a history of exposure to HCV but does not dis tinguish resolved from active infections. Since HCV antibodies can persist for years following a naturally resolved infection or successful antiviral therapy, fur ther testing with a nucleic acid test is required to de termine whether infection is active.
EMERGING OPPORTUNITIES TO ADDRESS HEPATITIS C
Since more than 1% of the U.S. population is esti mated to be chronically infected with HCV, 1 nurses are likely to see patients with chronic HCV infection
HAV Vaccination Recommendations 10
People recommended for HAV vaccination include • all children at one year.
• travelers to regions with intermediate or high rates of HAV.
• men who have sex with men.
• users of certain illegal drugs (injection and noninjection).
• people with clotting-factor disorders.
• people who work with HAV-infected primates or with HAV in a research laboratory.
• people with chronic liver disease, including chronic liver disease related to HBV and HCV.
Cell culture-derived HCV can remain infectious on surfaces up to six weeks.
in their practices. The recent rise in new HCV infec tions among young people further underscores the need to screen patients. Past efforts to address HCV have been hampered by therapies with limited effi cacy, a lack of awareness among providers, and low screening rates. Today, however, recently approved antiviral therapies have fewer adverse effects, with some having cure rates of 90% to 100% in clinical trials. 27 Furthermore, the ACA has expanded access to hepatitis screening while encouraging previously uninsured people to enter the health care system. All of this creates important opportunities for nurses to improve health outcomes for patients with viral hep atitis, particularly those with HCV.
Potential HCV manifestations. Since most patients with chronic HCV infection are asymptomatic until they develop advanced liver disease, it's important to maintain a high level of clinical suspicion. Mild to moderate liver damage may produce vague symp toms, such as fatigue, over a period ranging from years to decades. HCV, however, may also have a number of extrahepatic manifestations because it's associated with cryoglobulinemia and a lymphopro liferative immune complex disorder that causes ar thralgia, purpura, glomerular disease, peripheral neuropathy, central nervous system vascu litis, and reduced complement levels. 28 The CDC estimates that 29 • of those who are chronically infected with HCV, only half have been diagnosed.
• fewer than 38% of those with an HCV diagno sis have been referred to care.
• fewer than 11% of those referred to care have been treated. Identifying extrahepatic manifestations of chronic HCV infection may increase the likelihood of diagno sis, referral, and treatment (and now the possibility of cure). As we work to understand the true burden of HCV in the United States and how to better target the use of limited resources, accurate diagnosis and appropriate reporting are paramount.
EVALUATING LIVER DISEASE
All patients who have both a positive HCV antibody test and a positive nucleic acid test are considered to have ongoing infection. They should be evaluated for liver disease and receive counseling and disease man agement services. Liver disease evaluation involves determining liver function and the degree of liver dam age or fibrosis. Severity of fibrosis is usually described There is no specific test for acute HCV. If exposure to HCV within the past six months is suspected, test for HCV RNA or repeat HCV antibody test.
Serologic Marker Interpretation
HAV:
Of those who are chronically infected with HCV, only about half have been diagnosed.
in terms of a Metavir score, which ranges from F0, indicating no fibrosis, to F4, indicating cirrhosis. His torically, liver disease was evaluated on the basis of a liver biopsy, which was invasive, expensive, not with out discomfort, and susceptible to sampling error, meaning that the findings could vary depending on the portion of the liver sampled. In 2013, however, the U.S. Food and Drug Administration approved a noninvasive technology known as transient elastogra phy (FibroScan) for determining the degree of liver fi brosis. The technology's accuracy is improved when it is paired with serologic tests developed to monitor liver disease progression. Following liver evaluation, providers should discuss possible treatment options with patients and teach them how to maintain opti mal liver health, even if antiviral treatment is not pre scribed at that time.
HCV COUNSELING, EDUCATION, AND INTERVENTION
All patients with chronic HCV infection should re ceive education, counseling, and intervention to re duce the likelihood of liver disease progression and viral transmission to others. The CDC recommends that when providers share positive HCV test results with patients, they also evaluate patients' level of alcohol use. 26 Screening adults ages 18 and older for alcohol misuse and providing brief behavioral counseling to reduce alcohol misuse is a Grade B recommendation of the USPSTF. 30 As with HCV and HBV screening, screening for alcohol misuse is covered as a preventive service without copay under the ACA.
For people with substance use disorders and those at risk for developing such disorders, the Substance Abuse and Mental Health Services Administration recommends screening, brief intervention, and refer ral to treatment (SBIRT). 31 The SBIRT process pro vides a standardized framework that enables nurses to • quickly assess the severity of substance use and the appropriate level of treatment.
• focus on increasing the patient's insight and aware ness regarding substance use.
• motivate the patient to change risky behavior.
• identify patients in need of specialty care and help them gain access.
To protect the liver from further harm, counsel patients to • reduce or discontinue alcohol consumption.
• avoid taking new medications, including overthe counter and herbal agents, without first checking with their health care provider.
• obtain HIV risk assessment and testing.
• receive HAV and HBV vaccination (if not im mune).
To minimize the risk of transmission to others, advise patients not to • donate blood, tissue, or semen.
• share appliances that might come into contact with blood, such as toothbrushes, dental appliances, razors, or nail clippers.
• share needles or other injection equipment if us ing injection drugs.
Encourage overweight or obese patients to lose weight by following a healthy diet and staying physi cally active. Remind them that excess weight can cause or exacerbate liver damage.
HCV TREATMENT
The goal of HCV therapy is to achieve sustained vi ral response (SVR), or viral clearance, which repre sents a cure for HCV. 32 HCV treatments have been shown to be effective and to reduce the sequelae of
HBV Vaccination Recommendations
14-17
People recommended for HBV vaccination include • all infants at birth.
• older children who have not previously been vaccinated.
• people with household members who are at risk for or infected with HBV.
• health care and public safety workers who may be exposed to blood on the job.
• adults at risk for infection by sexual exposure, including men who have sex with men.
• people who use injection drugs.
• people with chronic liver disease, including chronic liver disease related to HCV.
• people with HIV infection.
• people with end-stage renal disease, including patients not yet treated with dialysis and those treated with hemodialysis, peritoneal dialysis, and home dialysis.
• residents and staff of facilities for developmentally disabled people.
• travelers to regions with intermediate or high rates of HBV.
• unvaccinated adults ages 19 to 59 with diabetes mellitus.
• anyone seeking long-term protection.
The goal of HCV therapy is to achieve sustained viral response, which represents a cure for HCV. untreated chronic infection. Treatments, however, are underutilized for a number of reasons. Notably, most patients are unaware of their HCV status, pa tients and many providers are unaware of new treat ments, and the policies of insurance companies and other payers often restrict access to treatment (by re quiring evidence of advanced liver fibrosis or cirrho sis before approving treatment, for example).
In addition, older HCV therapies were very diffi cult to tolerate, with many adverse effects and numer ous contraindications. Since 2001-and until very recently-the standard of care for HCV has been pe gylated interferon (peginterferon) injected weekly and paired with oral ribavirin. Both patients and providers have been anxious about initiating the 48week ther apy regimen because of its considerable adverse effect profile and relatively low rate of SVR. In two large phase 3 clinical trials of peginterferon plus ribavirin, at least 20% of participants reported adverse events, with 43% to 64% of these reporting fatigue, headache, and fever; 28% to 43% reporting nausea, alopecia, and in somnia; and 22% to 31% reporting depression. 33 In the United States, peginterferon plus ribavirin is no longer the treatment of choice for most genotypes of HCV, though it is listed in the current guidelines 28 as an alternative therapy for genotype 5 and is still used in some countries that have not yet approved the new est antiviral agents. The approval of new combination antiviral treatments-such as simeprevir (Olysio) plus sofosbuvir (Sovaldi), ledipasvir-sofosbuvir (Harvoni), and ombitasvir-paritaprevir-ritonavir packaged with dasabuvir (Viekira Pak)-which have fewer adverse effects, shorter treatment durations (12 to 24 weeks), and higher cure rates, has changed the HCV treat ment landscape. Additional HCV treatments are in development and are expected to become simpler and even more effective in curing chronic HCV. The avail ability of effective, curative treatments should serve as a great incentive to diagnose HCV early.
NATIONAL VIRAL HEPATITIS ACTION PLAN
In 2010, the Institute of Medicine (IOM) released a report that identified viral hepatitis as an underap preciated public health problem. 2 The report high lighted multiple barriers to viral hepatitis prevention and control and provided specific recommendations to improve efforts to stop the spread of viral hepati tis. In response to the IOM report, HHS developed and released Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral Hepatitis in May 2011. 2 On April 3, 2014, an updated version of the action plan was released for the years 2014 through 2016. 3 Detailing over 150 specific actions for federal agencies to take by 2016, the action plan sets goals within six major priority areas and provides a framework to focus the efforts of federal and nonfederal stakeholders in monitoring and measuring the achievement of these goals (see Key Elements of the National Viral Hepatitis Action Plan 2, 3 ). The major federal contributors to the action plan (HHS, the Department of Justice's Federal Bureau of Prisons, the Department of Housing and Urban Devel opment, and the Department of Veterans Affairs) rec ognize that its goals cannot be fully achieved without significant participation from other, nonfederal part ners. As such, the action plan seeks to engage a broad range of stakeholders in efforts to address viral hepati tis in the United States. Because of the pivotal role that nurses play as educators, care coordinators, and health care providers, they are uniquely positioned to provide critical leadership in advancing our nation's efforts to address the "silent epidemic" of viral hepatitis.
THE CRITICAL ROLE OF NURSES
Nurses play an important role in all six priority areas of the action plan. (2014) (2015) (2016) continues the pursuit of four overarching national goals to be achieved by 2020.
• Increase the proportion of people who are aware of their HBV infection from 33% to 66%.
• Increase the proportion of people who are aware of their HCV infection from 45% to 66%.
• Reduce by 25% the number of new cases of HCV infection.
• Eliminate mother-to-child transmission of HBV.
ajnonline.com advanced practice nurses and RNs can provide accu rate education [and] information regarding screening, testing, surveillance and evaluation of [the] impact of strategies. Nurses, and their vast health promotion net works, are poised to best assess, intervene and evaluate the impact of enforcing these recommendations." 34 In practice settings, nurses may be responsible for • reporting communicable diseases to state and lo cal health departments, thereby improving sur veillance data in their communities.
• assisting in disease outbreak investigations, help ing to identify sources of infection, and protecting people from exposure.
• educating patients on recommended vaccines, in cluding those for HAV and HBV, as research has shown that patients are more likely to accept a service if recommended by a health care provider. 35 • educating parents on infant HBV, ensuring that standing orders for HBV vaccination are in place, and vaccinating all infants in their care within 12 hours of birth.
• counseling patients with chronic HBV or HCV infection about liver health and treatment.
• assessing patients for alcohol or substance use, making referrals as appropriate. Nurses can also help to identify patients who are using substances at initial assessments and during an nual physical examinations, or when patients present with an accidental injury or wound that may be re lated to injecting drugs. Upon identifying a patient at risk, they can • refer patients to substance abuse treatment pro grams.
• confirm HBV vaccination completion and HCV screening.
• provide education on HCV transmission.
Nurses also play a significant role in infection con trol. They can identify and address threats to sterile technique before such threats put patients or other health care workers at risk for exposure to such blood borne pathogens as HBV and HCV. By ensuring that HBV vaccination coverage for all health care work ers is in accordance with the Occupational Safety and Health Administration guidelines, nurses can help protect their colleagues from HBV infection due to accidental needlestick. As leaders in preventing new hepatitis infections, providing care and treatment for those living with viral hepatitis, and ensuring the safety of patients and providers in health care settings, nurses are integral to achieving the goals of the HHS viral hepatitis action plan. ▼ For eight additional continuing nursing education activities related to hepatitis, go to www. nursingcenter.com/ce. • ACT-First-Training for primary care providers, free CME www.aasld.org/act-first-free-online-cme-course-primary-care-providers • HCV Treatment Guidelines from AASLD and the Infectious Diseases Society of America www.hcvguidelines.org
Resources for Nurses and Their Patients
Resources for Nurses
Resources for Patients
Hepatitis risk assessment
Are you at risk? Take this five-minute hepatitis risk assessment developed by the CDC and get a personalized report. 
